This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis. Eligible patients initiated on treatment with Mircera (methoxy polyethylene glycol-epoetin beta) will be followed for 6 months.
Inclusion Criteria:
Exclusion Criteria:
Greize, 69400, France
Mullhouse, 68100, France